Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

881
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
881
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

330
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
330
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.5K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

849
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
849
Introduction to Hemostasis01:05

Introduction to Hemostasis

11.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapy.

Cancer drug resistance (Alhambra, Calif.)·2026
Same author

Phenotypical and functional characterization of a HepG2 cell clone stably overexpressing cytochrome P450 (CYP) 2C9.

BMC research notes·2026
Same author

Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.

JHEP reports : innovation in hepatology·2026
Same author

<i>Arthrospira platensis</i> Mitigates LPA-Induced Endothelial Dysfunction: A Prospective, Placebo-Controlled Study.

Cells·2026
Same author

A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management.

Clinical hemorheology and microcirculation·2026
Same author

Super-resolution contrast-enhanced ultrasound (SR-CEUS) in solid organs.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2026

Related Experiment Video

Updated: Nov 27, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

874

Effect of Prostanoids on Human Platelet Function: An Overview.

Steffen Braune1, Jan-Heiner Küpper1, Friedrich Jung1

  • 1Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany.

International Journal of Molecular Sciences
|December 2, 2020
PubMed
Summary

Prostanoids significantly influence platelet function, impacting thrombosis and hemostasis. This review details how various prostanoids, like prostaglandin D2 and thromboxane A2, activate or inhibit platelets.

Keywords:
plateletsprostacyclinprostaglandinthromboxane

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

944
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.3K

Related Experiment Videos

Last Updated: Nov 27, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

874
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

944
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.3K

Area of Science:

  • Biochemistry
  • Physiology
  • Pharmacology

Background:

  • Prostanoids are vital bioactive lipid mediators involved in numerous physiological and pathophysiological processes.
  • Platelets are crucial for thrombosis and hemostasis, with their function modulated by blood and vascular wall mediators.

Purpose of the Study:

  • To review the specific effects of various prostanoids on platelet activation and aggregation.
  • To elucidate the distinct roles of different prostanoids in regulating platelet function.

Main Methods:

  • Literature review focusing on prostanoid signaling pathways in platelets.
  • Analysis of studies detailing prostanoid interactions with platelet receptors.

Main Results:

  • Prostanoids exhibit unique activity profiles, differentially regulating platelet activation and aggregation.
  • Specific prostanoids like PGD2, PGEs, PGF2α, PGI2, and TXA2 have distinct impacts on platelet function via their receptors.

Conclusions:

  • Prostanoids play a complex, dual role in hemostasis by either activating or inhibiting platelets.
  • Understanding these specific prostanoid actions is key to comprehending thrombosis and developing targeted therapies.